Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NRX Pharmaceuticals (NRXP) Change in Accured Expenses (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Change in Accured Expenses for 2 consecutive years, with $913000.0 as the latest value for Q4 2025.

Quarterly Change in Accured Expenses fell 90.97% to $913000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $501000.0 through Dec 2025, down 94.99% year-over-year, with the annual reading at $501000.0 for FY2025, 94.99% down from the prior year.
Change in Accured Expenses for Q4 2025 was $913000.0 at NRX Pharmaceuticals, up from -$210000.0 in the prior quarter.
The five-year high for Change in Accured Expenses was $10.1 million in Q4 2024, with the low at -$936000.0 in Q3 2024.